Company: SCLXW
Filing Date: 2025-08-14
Form Type: 424B3
Source: 0000950170-25-108223
Chunk: 91

Company: Scilex Holding Co
Filing Date: 2025-08-14
Form: 424B3
Chunk 91
---
anche B Notes (outstanding principal balance: $30.7 million and $38.0 million as of June 30, 2025 and December 31, 2024, respectively) |     |               | 21,420 |     |                   | 23,560 |
| Purchased Revenue Liability                                                                                                              |     |               |  7,600 |     |                   |  6,800 |
| Deferred Consideration with Romeg                                                                                                        |     |               |  2,667 |     |                   |  2,895 |
| Total indebtedness                                                                                                                       |     | $             | 50,138 |     | $                 | 45,416 |

Oramed Note As of June 30, 2025, the fair value of the Oramed Note outstanding was $18.5 million pursuant to the Scilex-Oramed SPA (see Note 7 titled “ Debt ” to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information). Tranche B Notes As of June 30, 2025, the fair value of the Tranche B Notes outstanding was $21.4 million pursuant to the Tranche B Securities Purchase Agreement (see Note 7 titled “ Debt ” to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information). Purchased Revenue Liability As of June 30, 2025, the fair value of the purchased revenue liability was $7.6 million pursuant to the ZTlido Royalty Purchase Agreement and Gloperba-Elyxyb Royalty Purchase Agreement (see Note 7 titled “ Debt ” to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for additional information). Deferred Consideration As of June 30, 2025, we have $2.7 million of deferred consideration related to minimum royalty payments that were included in the initial measurement of consideration transferred for the GLOPERBA license. Deferred consideration minimum royalty payments began in July 2023.

<div align='center'>55</div>

ZTlido, ELYXYB and GLOPERBA Royalties

In February 2013, Scilex Pharma became a party to a product development agreement (as amended, the “Product Development Agreement”) with Itochu and Oishi Koseido Co., Ltd. (“Oishi” and together with Itochu, the “Develop